BioSpace News Archive

Heartland Dental, the nation’s largest dental support organization serving approximately 1,400 supported dentists across more than 900 dental offices, today announced the opening of a non-clinical support office in St. Louis.

Below are experts from the ProfNet network who are available to discuss timely issues in your coverage area.

Bristol-Myers Squibb Company (NYSE:BMY) today issued the following statement regarding Celgene’s (NASDAQ:CELG) settlement with Lotus Pharmaceutical Co., Ltd. and Alvogen Pine Brook, LLC (collectively, “Alvogen”) relating to patents for Revlimid

Dr. Robin L. Smith is an internationally renowned doctor, business leader, entrepreneur, philanthropist, author, and global thought leader in regenerative medicine.

Watercrest Senior Living Group proudly announces the addition of Judi Donovan to the executive leadership team in a newly created role as vice president of startup operations.

Dr. Cap Lesesne of International Cosmetic Surgery in New York City announces a new body contouring treatment combining ultrasonic skin tightening technology with power assisted liposuction resulting in the ultimate body sculpting for both men and women.

CareWell Urgent Care Centers, an urgent care company which operates seventeen (17) urgent care centers in Massachusetts and one (1) in Rhode Island, will pay over $2.1 million dollars with interest to settle False Claims Act whistleblower claims against it, for its fraudulent billing of Medicare and Medicaid for services it provided which were unrelated to patients’ individual medical needs.

FEI Systems, a Columbia, Maryland-based provider of health information technology solutions, was awarded a contract from the Florida Department of Children and Families (DCF) in support of the State’s opioid response initiatives and the State Opioid Response Grant, awarded by SAMHSA.

W.L. Gore & Associates, Inc. (“Gore”), a global materials science company, announces its intention to participate in two upcoming life sciences conferences.

Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, will present new preclinical data for its first-in-class oral IRAK4 protein degrader, KYM-001, in MYD88-mutant lymphoma